Experimental melanoma combo trial shutters after just one patient

NCT ID NCT04093323

Terminated Disease control Sponsor: Roswell Park Cancer Institute Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase II trial tested a mix of a personalized dendritic cell vaccine and three immune-boosting drugs in people with advanced melanoma that no longer responded to PD-1/PD-L1 checkpoint inhibitors. The goal was to see if the combination could shrink tumors or slow their growth. However, the study was terminated after enrolling only one participant, so no meaningful results are available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: dendritic cell vaccine (aDC1) plus interferon alfa-2b, rintatolimod, and celecoxib
What this could lead to: If it worked, this combination might help melanoma patients whose tumors no longer respond to standard immunotherapy.
What could go wrong: The trial was terminated after enrolling only 1 person, so we have almost no data. It is very early and uncertain whether this approach is safe or effective.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HLA-A2 POSITIVE CELLS PRESENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

melanoma refractory malignant neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HLA-A2 POSITIVE CELLS PRESENT REFRACTORY MELANOMA

Contacts and locations

Locations

Roswell Park Cancer Institute

Buffalo, New York, 14263, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.